Brief: European Commission Grants Orphan Drug Designation For aTyr Pharma’s Efzofitimod For Treatment Of Systemic Sclerosis
22/06/2023 13:05
June 22 (Reuters) - aTyr Pharma Inc LIFE.O :
* EUROPEAN COMMISSION GRANTS ORPHAN DRUG DESIGNATION FOR
ATYR
PHARMA’S EFZOFITIMOD FOR TREATMENT OF SYSTEMIC SCLEROSIS
* ATYR PHARMA INC- EFZOFITIMOD PHASE 2 PROOF-OF-CONCEPT
STUDY IN
PATIENTS WITH SSC-ILD IS EXPECTED TO BEGIN IN Q3 OF 2023
Source text for Eikon: ID:nGNX6fQqJP
Further company coverage: LIFE.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan